-+ 0.00%
-+ 0.00%
-+ 0.00%

Biovica International Wins Work Order for Early-stage Oncology Study

MT Newswires·09/22/2026 05:21:30
Listen to the news
05:21 AM EDT, 09/22/2026 (MT Newswires) -- Biovica International (BIOVIC-B.ST) secured its first work order under a recently signed master services agreement with an operating unit of a US biotechnology company. The order, valued at $85,000, covers DiviTum TKa testing in a first-in-human phase 1 study of an oral cyclin-dependent kinase inhibitor in patients with advanced solid tumors, the Swedish blood-based biomarker assays maker said Tuesday. DiviTum TKa will be measured at several points during treatment to track changes in tumor proliferation across different dose levels.